Man Group PLC Nurix Therapeutics, Inc. Transaction History

Man Group PLC

  • $36 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$12.02 - $21.3 $134,924 - $239,092
11,225 New
11,225 $234,000
Q4 2023

Feb 14, 2024
SELL
$4.25 - $10.71 $20,106 - $50,669
-4,731 Reduced 19.73%
19,248 $198,000
Q3 2023

Nov 14, 2023
BUY
$7.86 - $10.08 $188,474 - $241,708
23,979 New
23,979 $188,000

Others Institutions Holding NRIX

# of Institutions
181
Shares Held
68.1M
Call Options Held
78K
Put Options Held
53.8K
View Full List

About Nurix Therapeutics, Inc.

NRIX Quotes by TradingView
  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $1.04B
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email